Brief: Hookipa Pharma Announces FDA Clearance Of Its Investigational New Drug Application For HB-700 For The Treatment Of KRAS-Mutated Cancers
24/04/2024 12:43
April 24 (Reuters) - HOOKIPA Pharma Inc HOOK.O :
* HOOKIPA PHARMA ANNOUNCES FDA CLEARANCE OF ITS
INVESTIGATIONAL
NEW DRUG APPLICATION FOR HB-700 FOR THE TREATMENT OF
KRAS-MUTATED CANCERS
Source text for Eikon: ID:nGNX61qRj6
Further company coverage: HOOK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hookipa Pharma
See all newsBrief: Hookipa Pharma Announces Sale Of Oncology Assets To Neotrail Therapeutics
Brief: Hookipa Pharma Announces Intention To Voluntarily Delist And Deregister Its Common Stock
Hookipa Pharma Inc Expected To Post A Loss Of $1.04 A Share: Earnings Preview
Brief: Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)